content_image/156005.jpg
<img src='content_image/156005.jpg'>

## Medicines That Fuel Our Growth 

At Bristol-Myers Squibb, we rely on a strong lineup of products to acceler- ate our growth and help fuel research for promising future possibilities. Key brands today include Orencia  (abata- cept) for rheumatoid arthritis (RA); Sprycel  (dasatinib) and Erbitux  (cetux- imab) for cancer; reyataz  (atazanavir), Atripla  (efavirenz with emtricitabine and tenofovir) and Sustiva  (efavirenz) for HIV/AIDS; Baraclude  (enteca- vir) for hepatitis B; and Onglyza (saxagliptin), and Kombiglyze  XR and Komboglyze  (saxagliptin and metfor- min HCl fixed-dose combinations) for diabetes (also see pages 16-17). Not only is use of many of these therapies on the rise for approved indications, but in many cases, new research is seeking to examine their ability to benefit more patients. 

## Orencia 

Orencia  crossed $1 billion in annual sales in 2012. Additional growth has come with the approval of subcutane- ous (SC) administration in the U.S., Europe and Australia, allowing patients who wish to do so to self-administer the medication. Worldwide, SC formula- tions currently represent about 70 per- cent of the total RA biologics market, 80 percent in Europe alone. With its unique mechanism of action, differ- ing from standard anti-tumor necrosis factor (TNF) agents, and a balance of efficacy and safety, Orencia  provides an important biologic alternative to stan- dard anti-TNF treatments. Also, Orencia is the only biologic agent currently avail- able in both intravenous (IV) and SC formulations for the treatment of RA. New clinical data from the AMPLE study, presented last year, further 

supports the efficacy of Orencia . The first large head-to-head trial of its kind in RA, AMPLE  found that Orencia showed comparable efficacy to a com- monly prescribed TNF inhibitor. Further exploring additional uses, Phase III trials are beginning in lupus nephritis, a complex disease with a high unmet need, and in psoriatic arthritis. 

## Sprycel and Erbitux 

Sprycel  became a billion-dollar prod- uct globally for the first time in 2012, having established itself as an impor- tant medicine to treat chronic myeloid leukemia (CML) in both treatment- naïve and refractory patients. Physi- cians appreciate the fast and deep responses to the disease that Sprycel offers and its ability to achieve early response milestones. The approval of Sprycel  as a first-line therapy has helped provide additional benefits for patients newly diagnosed with CML. Also, patients and physicians increasingly value the demonstrated long-term benefit and the simplicity of Sprycel ’s once-daily dosing regimen. 

Sprycel  was successfully launched in China in mid-2012 for second-line CML treatment, becoming our compa- ny’s first oncology therapy launched in China in 17 years. To further address areas of unmet medical need, ongo- ing studies are examining whether CML patients who have significant responses to Sprycel  can eventually come off therapy and maintain their responses. Early studies also are assessing Sprycel  in mutation-defined lung cancer and in pancreatic cancer. 

In 2012, Erbitux  was approved for use as a first-line treatment option for patients with KRAS-mutation-negative 

(wild type) metastatic colorectal cancer (mCRC) (about 60 percent of the total mCRC population). Erbitux was initially approved in 2004 as a second-line or later treatment option for mCRC. In 2011, Erbitux  also received approval as a first-line treat- ment option in recurrent metastatic squamous cell carcinoma of the head and neck. The new indications are important advances in the treatment of these two prevalent tumor types, offering both prolonged survival and increased response rates. 

## Reyataz , Atripla and Sustiva 

A long-time leader in HIV treatments, Bristol-Myers Squibb was the first (partnering with Gilead) to bring a single-tablet regimen to the market with Atripla . Despite an increasingly competitive environment, Atripla remains the number-one-prescribed single tablet HIV regimen in the U.S., a position built on a foundation of proven efficacy and long-term virologic sup- pression. reyataz , launched in 2003, exhibits durable viral control and a strong resistance profile. It is used in both treatment-naïve and drug-resistant patients and plays an important role in the treatment of women, with data supporting its efficacy and safety in this population and with a unique label for use in pregnant women with HIV/AIDS. 

Indeed, we have placed a special focus on women living with HIV, a vulnerable and growing population. 

In Europe, for example, where women represent one-third of new HIV diagnoses, the company, in partner- ship with an independent faculty that includes health care providers and patient groups, has launched SHE, an 

